The Future of Pharma Samir Gondalia, ISPE Boston

My guest in this episode of The Future of Pharma is Nikhil Bhojwani. 
Nikhil is an entrepreneur, investor, strategist, and TedTalk speaker. He is a Managing Partner at Recon Strategy, a boutique consulting firm that he founded in 2010. At Recon Strategy, Nikhil works with executives and boards on strategy at the portfolio and business-unit levels for payers, hospitals, life science, and digital health companies. 
Nikhil stays close to the startup community as an investor, board member, and advisor to several companies. These have included CIC Health, a national leader in COVID testing and vaccinations, which was founded based on a blueprint set out in an HBR article Nikhil co-authored with Dr. Atul Gawande. 
Nikhil was the 2023 Dorothy R. Eisenberg Visiting Professor at Harvard Medical School/ Brigham and Women's Hospital, where for the 50th anniversary lecture of this series, he presented a lecture on the future of AI in healthcare. 
He has also lectured at Harvard Business School and the Harvard School of Public Health and is a member of the Massachusetts Governor's AI task force healthcare working group.
In this wide ranging talk, we discuss about
- What AI can do that humans can't
- How Moderna is using AI to respond to regulatory queries (among other things)
- AI in pharma competitive landscape (and it's not just technology)
- Where multiple big companies need to collaborate due to the scale
- His tedtalk ("Unlock potential of Generative AI by Conquering the Spooky Mountain")
- Responsible use of AI
- Rational and irrational fears about AI
- Why AI's growth seems scarier than other historical technological advances
- Real impact in the pharmaceutical industry (and on the regulatory agencies)
- And instead of writing a book, what he would do with the existing knowledge.
Hope you enjoy this informative talk with Nikhil Bhojwani.

My guest in this episode is Dr. Harsha Rajasimha, CEO/founder of Jeeva Clinical Trials.
We talked about the pharmaceutical industry's blackbox - clinical trials.
Personal tragedy inspired him to dedicate his life to make technology more efficient for healthcare solutions including AI and generative AI.
We discussed the complexities of clinical trials, its patient recruitment, and data unavailability challenges, and why we must make them more efficient
He is also the founder of a non-profit, IndoUSRare, which as the name implies bridges the rare disease treatment and awareness gap between the US and Indian diaspora. 
We also discussed the people and companies with the similar inspiring stories such as John Crowley from Amicus Therapeutics, and Terry Pirovolakis from Elpida Therapeutics.
Listen to Harsha's interview if you're looking for a doze of inspiration and motivation.

My guest today is Hon. Prof. Dr. Tom Chittenden, but he prefers to go by Tom.
He is the Chief Scientific Officer and President of R&D at BioAI Company and leads scientific research operations and ongoing development and implementation of the BioAI Health PREDICT-X Drug Discovery and Development platform.
Tom Chittenden is an Honorary Professor of AI in Biomedicine at Queen Mary University of London. His research has been published in top-tier scientific journals, including Nature and Science. Tom is regarded as one of the world’s leading authorities on causal AI in the biomedical sciences. Over the past decade, he has directed commercially successful computational teams in several globally relevant areas, including multimodal AI/ML strategies for cardio vascular disease, cancer, COVID-19, Alzheimer’s, and Parkinson’s diseases. In 2019, he was named among the top 100 Pioneers in Drug Discovery and Advanced Healthcare by Forbes Magazine. 
As a professor, he has taught at Boston Children’s Hospital, Harvard Medical School, and MIT. He holds multiple Doctorates in Molecular Cell Biology and Biotechnology and Computational Statistics. 
In this fascinating talk, Tom and I discuss the real potential and challenges in the AI space, how it's going to affect the future of the Pharmaceutical industry, and what you can do about it.
Here's Honorary Professor Tom Chittenden.

My guests today are the dynamic husband-wife duo of Alpesh and Jigisha Gandhi who jointly run Ami Polymer Pvt. Ltd. which is a leading manufacturer of silicon tubing something we use a lot in the life science industry. Starting with Alpesh and later with Jigisha, Ami Polymer is a leading silicon tubing manufacturing company in India and played an important role in COVID vaccine manufacturing.
Alpesh Gandhi did his engineering in Rubber Technology from L. D. College of Engineering, Ahmedabad, India. The same college where I did my Chemical Engineering. Then he did his MBA from Jamnalal Bajaj Institute of Management Studies. He co-founded Ami Polymer Pvt. Ltd. in the late 90s. 
Jigisha Gandhi studied commerce at the University of Mumbai and is the director of Ami Polymer Pvt. Ltd. She's been bestowed with numerous awards by Universities, magazines, and the government for her achievements in the business world, including being profiled in a book "Eves Against the Odds" featuring the most powerful women entrepreneurs in India.
Here are Alpesh and Jigisha Gandhi sharing their fascinating journey from humble beginnings to running a global company and what they think the future holds for the pharma industry.

My guest in this episode is Gareth Shaw. Gareth Shaw is the President, the UK & Europe of Doceree, the first global network of physician-only platforms for programmatic messaging. Prior to joining Doceree, Gareth was the General Manager, Global Programmatic, of PulsePoint where he led the programmatic and operations divisions.
Previously, he has held roles at Yahoo! and Experian. 
Throughout his career, Gareth has gained vast experience in sales and operations across the digital media and advertising technology sectors. He has a well-regarded background in building high-performance teams and implementing strategic plans to facilitate the growth of his organizations. 
 

My guest in this episode is Lyndsee Manna.
Lyndsee is an EVP at Arria NLG, where along with her colleagues, she helps businesses derive actionable intelligence from data to make better decisions. That's the simplistic version and we go into a lot more details.
In this wide-ranging episode, we talk about math, words, language, writing, technology, data analytics, success, failure, and personal choices.
A standout quote from her is, "There are no failures. There are only lessons."
I had a great time talking to Lyndsee, discussing the future possibilities, and learning about AI.